These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28552765)

  • 1. Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer.
    Wan R; Wang Z; Lee JJ; Wang S; Li Q; Tang F; Wang J; Sun Y; Bai H; Wang D; Zhao J; Duan J; Zhuo M; An T; Wu M; Chen Z; Yang Z; Wang J
    J Thorac Oncol; 2017 Sep; 12(9):1376-1387. PubMed ID: 28552765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
    Wang W; Song Z; Zhang Y
    Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day.
    Wang J; Bai H; Hong C; Wang J; Mei TH
    Thorac Cancer; 2017 Jul; 8(4):312-319. PubMed ID: 28437026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma].
    Cao Z; Wang J; Qin N; Li K; Lv J; Wang J; Yang X; Li X; Zhang H; Zhang Q; Long H; Shu C; Ma L; Zhang S
    Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):84-90. PubMed ID: 32093452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 7. Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.
    Yang K; Li J; Zhao J; Ren P; Wang Z; Wei B; Dong B; Sun R; Wang X; Groen HJM; Ma J; Guo Y
    Anal Chem; 2018 Oct; 90(19):11203-11209. PubMed ID: 30156405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A.
    Park CK; Lee SY; Lee JC; Choi CM; Lee SY; Jang TW; Oh IJ; Kim YC
    Thorac Cancer; 2021 Feb; 12(4):444-452. PubMed ID: 33270375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
    Arrieta O; Hernandez-Martinez JM; Montes-Servín E; Heredia D; Cardona AF; Molina-Romero C; Lara-Mejía L; Diaz-Garcia D; Bahena-Gonzalez A; Mendoza-Oliva DL
    Cancer Biomark; 2021; 32(2):123-135. PubMed ID: 34057135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
    Zheng D; Ye X; Zhang MZ; Sun Y; Wang JY; Ni J; Zhang HP; Zhang L; Luo J; Zhang J; Tang L; Su B; Chen G; Zhu G; Gu Y; Xu JF
    Sci Rep; 2016 Feb; 6():20913. PubMed ID: 26867973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
    Zhang C; Wei B; Li P; Yang K; Wang Z; Ma J; Guo Y
    PLoS One; 2017; 12(3):e0173524. PubMed ID: 28333951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
    Roh MS; Yoon NB; Lee S; Kang BH; Um SJ; Lee DH; Son C
    J Cancer Res Ther; 2020; 16(4):843-849. PubMed ID: 32930128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment.
    Zhu L; Zhang S; Xun Y; Jiang Y; Xia B; Chen X; Wang L; Jiang H; Ma S
    Pathol Oncol Res; 2018 Oct; 24(4):843-851. PubMed ID: 28868565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical value of droplet digital polymerase chain reaction method in detecting plasma circulating tumor deoxyribonucleic acid epidermal growth factor receptor mutations in advanced pulmonary adenocarcinoma patients].
    Ma L; Lü JL; Li K; Wang JH; Yang XJ; Li X; Zhang H; Zhang Q; Qin N; Zhang SC
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(29):2336-2340. PubMed ID: 30107692
    [No Abstract]   [Full Text] [Related]  

  • 17. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.
    Normanno N; Denis MG; Thress KS; Ratcliffe M; Reck M
    Oncotarget; 2017 Feb; 8(7):12501-12516. PubMed ID: 27980215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer.
    Ma M; Shi C; Qian J; Teng J; Zhong H; Han B
    Gene; 2016 Oct; 591(1):58-64. PubMed ID: 27370697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
    Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
    Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.
    Lee Y; Park S; Kim WS; Lee JC; Jang SJ; Choi J; Choi CM
    Thorac Cancer; 2018 Sep; 9(9):1104-1110. PubMed ID: 29989342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.